查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611831

破伤风类毒素疫苗市场：按疫苗类型、年龄和最终用户划分 - 全球预测 2025-2030

Tetanus Toxoid Vaccine Market by Vaccine Type (Diphtheria and Tetanus (DT), Diphtheria,Tetanus, and Pertussis (DTaP), Tetanus, Diphtheria and Pertussis (Tdap)), Age (Adults, Neonatal), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年破伤风类毒素疫苗市值为55.8亿美元，预计2024年将达58.6亿美元，复合年增长率为6.75%，到2030年将达到88.3亿美元。

破伤风类毒素疫苗是一种重要的医疗产品，因其能够预防破伤风，破伤风是一种以肌肉僵硬和痉挛为特征的致命细菌感染疾病。这种疫苗的需求源于它在保护可能因割伤或受伤而接触破伤风梭菌的人们方面的作用，特别是在医疗机构、军队以及开发中地区的分娩过程中。它的用途还扩展到各种公共卫生项目，其中常规免疫接种和加强注射至关重要。该疫苗的最终用途包括医院、诊所和社区健康保健服务，并大力推动扩大其在低收入和中等收入国家的使用。目前的破伤风类毒素疫苗市场受到全球疫苗接种意识不断增强、政府支持性免疫计画以及给药技术进步等因素的影响。预防多种疾病的组合疫苗正在引起人们的关注，为製造商创新和应对不同的人口趋势铺平了道路。然而，它面临着挑战​​，包括疫苗交付的物流问题、偏远地区缺乏认识以及某些人群对接种疫苗犹豫不决。此外，在对负担得起的医疗保健解决方案的需求中，监管障碍和定价压力正在限制市场。儘管有这些挑战，但仍有创新空间的领域包括单剂疫苗、改进的低温运输技术以及数位控制的输送系统，以提高效率和疫苗接种率。在公共卫生优先事项以及与非政府组织合作以提高疫苗接种覆盖率的推动下，市场倾向于稳定和有弹性的成长模式。公司可以透过投资教育宣传活动和开发更具成本效益、更容易管理、更容易获得公众接受的疫苗而受益。

主要市场统计
基准年[2023] 55.8亿美元
预计年份 [2024] 58.6亿美元
预测年份 [2030] 88.3亿美元
复合年增长率（%） 6.75%

市场动态：快速发展的破伤风类毒素疫苗市场的关键市场洞察

破伤风类毒素疫苗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球破伤风流行率高
    • 破伤风疫苗的成本更低且供应范围更广
  • 市场限制因素
    • 因疫苗品质缺陷而导致产品召回的可能性
  • 市场机会
    • 政府为提高意识和疫苗接种计划所做的努力
    • 改善各国的低温运输和医疗基础设施
  • 市场挑战
    • 与疫苗相关的副作用

波特的五力战略工具驾驭破伤风类毒素疫苗市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解破伤风类毒素疫苗市场的外部影响

外部宏观环境因素在塑造破伤风类毒素疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解破伤风类毒素疫苗市场的竞争格局

对破伤风类毒素疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵破伤风类毒素疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估破伤风类毒素疫苗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製破伤风类毒素疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，破伤风类毒素疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 破伤风在世界各地广泛传播
      • 破伤风疫苗价格低廉且广泛使用
    • 抑制因素
      • 因疫苗品质缺陷而导致产品召回的可能性
    • 机会
      • 政府关于宣传和疫苗接种计划的倡议
      • 改善各国的低温运输和医疗基础设施
    • 任务
      • 与疫苗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以疫苗类型分類的破伤风类毒素疫苗市场

  • 白喉和破伤风 (DT)
  • 白喉、破伤风和百日咳 (DTaP)
  • 破伤风、白喉、百日咳 (Tdap)

第七章依年龄分類的破伤风类毒素疫苗市场

  • 成人
  • 新生

第八章破伤风类毒素疫苗市场：依最终用户分类

  • 诊所
  • 医院

第九章美洲破伤风类毒素疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区破伤风类毒素疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲破伤风类毒素疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AJ Vaccines A/S
  • Astellas Pharma Inc.
  • BB-NCIPD Ltd.
  • Bharat Biotech Ltd.
  • Bio Farma
  • Biological E. Limited
  • Dano Vaccines & Biologicals Pvt. Ltd.
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Incepta Vaccine Ltd.
  • MEDZEEL LIFESCIENCE
  • Merck & Co, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B1685377AB26

The Tetanus Toxoid Vaccine Market was valued at USD 5.58 billion in 2023, expected to reach USD 5.86 billion in 2024, and is projected to grow at a CAGR of 6.75%, to USD 8.83 billion by 2030.

The Tetanus Toxoid Vaccine is a crucial medical product defined by its ability to prevent tetanus, a potentially fatal bacterial infection characterized by muscle stiffness and spasms. The necessity of the vaccine stems from its role in safeguarding individuals who suffer cuts, wounds, or injuries that may expose them to Clostridium tetani, especially in healthcare facilities, military units, and during childbirth in developing regions. Its application extends to various public health programs, where it is crucial for routine immunizations and booster shots. The end-use scope of the vaccine encompasses hospitals, clinics, and community healthcare services, with a significant push towards increasing access in low- and middle-income countries. The current market for the tetanus toxoid vaccine is influenced by factors such as increasing global awareness of immunization, supportive government vaccination programs, and advancements in delivery technologies. Opportunities are blooming with the rising focus on combination vaccines that protect against multiple diseases, presenting avenues for manufacturers to innovate and reach diverse demographics. However, market growth faces challenges such as logistical issues in vaccine delivery, lack of awareness in remote areas, and vaccine hesitancy in certain populations. Additionally, the market is constrained by regulatory hurdles and pricing pressures amidst the need for affordable healthcare solutions. Despite these challenges, areas ripe for innovation include single-dose vaccines, improved cold chain technologies, and digitally controlled delivery systems that enhance efficiency and coverage. The nature of the market tilts towards a stable yet resilient growth pattern, driven by public health priorities and collaborations with non-governmental organizations to boost inoculation rates. Businesses stand to gain by investing in educational campaigns and developing cost-effective, easy-to-administer vaccines for broader reach and heightened public acceptance.

KEY MARKET STATISTICS
Base Year [2023] USD 5.58 billion
Estimated Year [2024] USD 5.86 billion
Forecast Year [2030] USD 8.83 billion
CAGR (%) 6.75%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tetanus Toxoid Vaccine Market

The Tetanus Toxoid Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant prevalence of tetanus worldwide
    • Low cost and wide availability of tetanus vaccine
  • Market Restraints
    • Potential product recall due to vaccine quality defects
  • Market Opportunities
    • Government initiatives for awareness and immunization programs
    • Improving cold chain and healthcare infrastructure across countries
  • Market Challenges
    • Side effects associated with vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Tetanus Toxoid Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tetanus Toxoid Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tetanus Toxoid Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tetanus Toxoid Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tetanus Toxoid Vaccine Market

A detailed market share analysis in the Tetanus Toxoid Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tetanus Toxoid Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tetanus Toxoid Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tetanus Toxoid Vaccine Market

A strategic analysis of the Tetanus Toxoid Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tetanus Toxoid Vaccine Market, highlighting leading vendors and their innovative profiles. These include AJ Vaccines A/S, Astellas Pharma Inc., BB-NCIPD Ltd., Bharat Biotech Ltd., Bio Farma, Biological E. Limited, Dano Vaccines & Biologicals Pvt. Ltd., GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd., Incepta Vaccine Ltd., MEDZEEL LIFESCIENCE, Merck & Co, Inc., Panacea Biotec Limited, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Tetanus Toxoid Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccine Type, market is studied across Diphtheria and Tetanus (DT), Diphtheria,Tetanus, and Pertussis (DTaP), and Tetanus, Diphtheria and Pertussis (Tdap).
  • Based on Age, market is studied across Adults and Neonatal.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant prevalence of tetanus worldwide
      • 5.1.1.2. Low cost and wide availability of tetanus vaccine
    • 5.1.2. Restraints
      • 5.1.2.1. Potential product recall due to vaccine quality defects
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives for awareness and immunization programs
      • 5.1.3.2. Improving cold chain and healthcare infrastructure across countries
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tetanus Toxoid Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Diphtheria and Tetanus (DT)
  • 6.3. Diphtheria,Tetanus, and Pertussis (DTaP)
  • 6.4. Tetanus, Diphtheria and Pertussis (Tdap)

7. Tetanus Toxoid Vaccine Market, by Age

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Neonatal

8. Tetanus Toxoid Vaccine Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Tetanus Toxoid Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tetanus Toxoid Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tetanus Toxoid Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AJ Vaccines A/S
  • 2. Astellas Pharma Inc.
  • 3. BB-NCIPD Ltd.
  • 4. Bharat Biotech Ltd.
  • 5. Bio Farma
  • 6. Biological E. Limited
  • 7. Dano Vaccines & Biologicals Pvt. Ltd.
  • 8. GlaxoSmithKline PLC
  • 9. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 10. Incepta Vaccine Ltd.
  • 11. MEDZEEL LIFESCIENCE
  • 12. Merck & Co, Inc.
  • 13. Panacea Biotec Limited
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.
  • 16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. TETANUS TOXOID VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. TETANUS TOXOID VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TETANUS TOXOID VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TETANUS TOXOID VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA AND TETANUS (DT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA,TETANUS, AND PERTUSSIS (DTAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY TETANUS, DIPHTHERIA AND PERTUSSIS (TDAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY NEONATAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023